FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: Although FcRn inhibitors offer advantages in dosing convenience and a clear mechanism, their safety in CIDP treatment, transition strategies, and personalized application criteria require further research to optimize clinical use and prevent irreversible neurological damage [69].